Alyeska Investment Group
RETA

Alyeska Investment Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Alyeska Investment Group’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-50,982
Closed -$5.2M – 669
2023
Q2 		$5.2M Buy
+50,982
New +$4.82M 0.04% 331
2018
Q2 		– Sell
-152,323
Closed -$3.12M – 547
2018
Q1 		$3.12M Sell
152,323
-53,252
-26% -$1.37M 0.03% 320
2017
Q4 		$5.82M Buy
205,575
+114,527
+126% +$3.2M 0.05% 253
2017
Q3 		$2.83M Buy
+91,048
New +$2.74M 0.02% 329

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Alyeska Investment Group's RETA Position: Q3 2023 in Review

Alyeska Investment Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 50,982 shares — an estimated $5.2M sold.

Alyeska Investment Group first reported a position in RETA in Q3 2017 and held it in 4 quarters. The position peaked at $5.82M in Q4 2017. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Alyeska Investment Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Alyeska Investment Group sold 50,982 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $5.2M.
  • Alyeska Investment Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2017 and held it in 4 quarters.
  • Alyeska Investment Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $5.82M in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Alyeska Investment Group's 13F filing for Q3 2023, filed 14 Nov 2023.